Clinical Efficacy of Hormone Replacement Therapy in Treating Perimenopausal Women With MGD

Zhejiang University

Status: Unknown

Conditions: Meibomian Gland Dysfunction

Treatments: Drug: Hormone replacement therapy

Study type: Observational

Funder types: Other

Identifiers

NCT04962386

研2019-363

Details and patient eligibility

About

This project aims to evaluate the possible relationship between MGD and HRT in perimenopausal women

Full description

This project aims to: 1. Evaluate the possible relationship between MGD and HRT in perimenopausal women; 2. To explore the mechanism of HRT treatment on MGD through clinical trials;3. Optimize treatment methods by exploring the mechanism, and develop more personalized and systematic treatment plans for MDG patients in the perimenopausal period.

Enrollment: 30 estimated patients

Sex: Female

Ages: 25 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Perimenopausal women who did not undergo HRT

Exclusion criteria

• (1) Patients who meet any of the following criteria will not be eligible for inclusion in the study: ① Unable or unwilling to sign a consent form, or unable to follow study procedures.

  (2) Have worn contact lenses in the past month, have had anterior segment surgery in the past 3 months, have a history of corneal refractive surgery, and have eye diseases other than dry eyes.Use of topical medicines other than eye lubricants in the past 3 months.Use of total body immunomodulators, tetracycline, or glucocorticoids in the past 3 months.Occlusion of lacrimal dots or eye trauma in the past 3 months.③ is pregnant, nursing or breastfeeding, or has received HRT treatment.

  ④ All patients with DE related diseases, such as diabetes mellitus, Sjogren syndrome, Stevens-Johnson syndrome.All participants were free of cancer, liver disease, kidney disease, stroke, transient cerebral ischemia, myocardial infarction, peptic ulcer, gout, or mental illness.Women who used anticoagulants, corticosteroids or vitamin A, vitamin E or beta-carotene were also excluded.

Trial design

30 participants in 2 patient groups

Perimenopausal women who did not undergo HRT

Description:

Perimenopausal women who did not undergo HRT at baseline. And they did not receive any other drugs

Treatment:

Drug: Hormone replacement therapy

Perimenopausal women who did undergo HRT

Description:

Perimenopausal women who did undergo HRT received estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV. Weesp, The Netherlands).Take this medicine once a day. A course of treatment was defined as 28 days of continuous treatment.

Treatment:

Drug: Hormone replacement therapy